About the Authors

Ignacio Garrido-Laguna

Ignacio.garrido-laguna@hci.utah.edu

Affiliation Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

David S. Hong

Affiliation Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

Filip Janku

Affiliation Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

Ly M. Nguyen

Affiliation Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

Gerald S. Falchook

Affiliation Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

Siqing Fu

Affiliation Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

Jenifer J. Wheler

Affiliation Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

Rajyalakshmi Luthra

Affiliation Department of Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

Aung Naing

Affiliation Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

Xuemei Wang

Affiliation Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

Razelle Kurzrock

Affiliation Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

Competing Interests

The authors have declared that no competing interests exist.

Author Contributions

Conceived and designed the experiments: IGL DSH FJ XW RK. Performed the experiments: IGL RL. Analyzed the data: IGL DSH FJ XW RK. Contributed reagents/materials/analysis tools: IGL DSH FJ LMN GSF SF JJW RL AN XW RK. Wrote the paper: IGL DSH FJ XW RK.